Staying on Track: What the GLP-1 Withdrawal Trials Mean for Patients Who Move or Travel Abroad

09 Nov Staying on Track: What the GLP-1 Withdrawal Trials Mean for Patients Who Move or Travel Abroad

For people who relocate, the biggest GLP-1 risk is often an unplanned break in care.

MedicalResearch.com: What is the background for this discussion?

Dr. Yelamo: GLP-1 receptor agonists such as semaglutide, and the dual GIP/GLP-1 agonist tirzepatide, have changed how we treat obesity. But they are long-term treatments, and long-term treatment assumes a stable doctor, pharmacy and supply. Many of my patients don’t have that. They are Americans, Britons and other Europeans who have just moved to Spain, retirees who split the year between two countries, or travelers who started treatment at home. When they cross a border, the prescription, the brand name and the follow-up often stay behind. For them, the safest first step is a fresh GLP-1 medical assessment with a locally licensed doctor, ideally before their supply runs out.

MedicalResearch.com: What does the evidence say about stopping treatment?

Dr. Yelamo: It is clear and consistent. In STEP 1, adults without diabetes who took semaglutide 2.4 mg weekly for 68 weeks lost 14.9% of body weight on average, compared with 2.4% on placebo.¹ In the off-treatment extension, participants regained about two-thirds of the weight they had lost within a year of stopping, and most cardiometabolic improvements drifted back toward baseline.²

SURMOUNT-4 tested the question directly with tirzepatide. After a 36-week lead-in with a mean loss of 20.9%, patients were randomized to continue or switch to placebo. Over the next 52 weeks, those switched to placebo regained 14.0% of their weight, while those who continued lost a further 5.5%.³

The practical message is that obesity behaves like other chronic conditions. An interruption is not neutral.

MedicalResearch.com: Why are people living abroad at particular risk?

Dr. Yelamo: In my practice I see four recurring problems:

• Prescription gaps. A US prescription is not valid at a Spanish pharmacy. Patients often assume they can simply refill, then go weeks without treatment.
• Unsupervised restarts. After several missed weekly doses, patients may restart at their old dose and get significant nausea or vomiting. Product labels advise discussing a lower restart dose with the prescriber.
• Falsified products. The EMA (European Medicines Agency) has warned about falsified semaglutide pens found in the EU supply chain.⁴ Products bought online or outside licensed pharmacies are a real risk.
• No one owns follow-up. Side effects, other medicines and plans such as pregnancy or surgery need a doctor who knows the patient.

Medication works alongside nutrition, activity and sleep, not instead of them.

MedicalResearch.com: What should readers take away?

Dr. Yelamo: If you are on a GLP-1 medicine and planning a move or a long stay abroad, plan it like any other chronic treatment:

• Before leaving, ask your prescriber for a written summary: the medicine, current dose, start date, side effects and recent blood tests.
• Find a licensed local doctor early, before your supply runs out, rather than after a gap.
• Buy only from licensed pharmacies, with a valid local prescription.
• If you have missed doses, don’t restart at full dose without advice.
• Know the warning signs that need urgent care: severe, persistent abdominal pain, signs of dehydration, or swelling of the face or throat.

Telemedicine can help with continuity, but it is not a shortcut to a prescription. A proper assessment reviews your history, other medicines and goals, and a prescription is issued only when it is clinically appropriate. These medicines are also not suitable for everyone, for example during pregnancy or breastfeeding.

MedicalResearch.com: What recommendations do you have for future research?

Dr. Yelamo: We have good data on what happens when treatment stops in a trial. We have much less on unplanned interruptions in real life: how often internationally mobile patients lose access, how long the gaps last and how they restart. Registry and pharmacy-dispensing studies that follow patients across borders would help clinicians plan care for a growing group.

MedicalResearch.com: Any disclosures?

Dr. Yelamo: I run a private telemedicine practice that offers weight-management consultations, including assessment for GLP-1 treatment where appropriate. I have no financial relationships with pharmaceutical manufacturers.

For a broader overview of supervised treatment, see this MedicalResearch.com overview of why clinical oversight matters with GLP-1 treatment.

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. MedicalResearch.com and Eminent Domains Inc. do not warrant or endorse products or claims made by third party links. Always seek the advice of your physician or other qualified health provider and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on November 9, 2026 by Marie Benz MD FAAD